Today: 1 July 2026
Browse Category

NASDAQ:PFSA 29 October 2025 - 31 December 2025

Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring

Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring

NEW YORK, December 31, 2025, 04:32 ET — Premarket Profusa Inc shares were down about 12% at 10.7 cents in premarket trading on Wednesday, after soaring 78% to 12.2 cents in the prior session as investors reacted to the company’s debt restructuring. Tuesday’s session saw the stock trade between 10.8 cents and 17 cents, with volume jumping to about 822 million shares. StockAnalysis
31 December 2025
·
Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound?

Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound?

Profusa’s after-hours surge came on the heels of a positive company update. The California-based digital health firm announced it has completed key manufacturing initiatives, creating enough production capacity to supply more than twice the units needed to meet its 2026 revenue goals for the Lumee™ continuous oxygen sensor systembenzinga.com. Fred Knechtel, Profusa’s CFO, said the team is “laser-focused on achieving revenue from sales of Lumee tissue oxygen monitoring systems… at the start of the second quarter of 2026,” with inventory shipments to distributors planned in Q1 2026benzinga.com. To support that timeline, Profusa finished the first full run of sensor production in October and even began production of its Lumee injector “pens,” according to the updatebenzinga.com. The Wireless Lumee Oxygen Platform includes a tiny injected biosensor and a low-profile patch that reads the sensor’s signal and transmits data wirelesslyprnewswire.com.
29 October 2025
·

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Go toTop